1.Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.
2.Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4: 47-53.
3.Zhang MB, Meng ZL, Mao Y, Jiang X, Xu N, Xu QH, et al. Cervical lymph node metastasis prediction from papillary thyroid carcinoma US videos: a prospective multicenter study. BMC Med. 2024; 22: 153.
4.Tan H, Gu Y, Xiu Y, Han X, Wen Q, Lv Z, et al. Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial. JAMA Netw Open. 2024; 7: e2443407.
5.Chen C, Cao J, Wang Y, Han X, Zhang Y, Zhuang S. Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China. Thyroid : official journal of the American Thyroid Association. 2023; 33: 474-83.
6.Gao J, Wang X, Zhang L, Li J, Qin X, Wang L, et al. Prevalence and predictors of psychological distress among patients with thyroid cancer during transitional period in China: a cross-sectional study. Support Care Cancer. 2022; 30: 7903-11.
7. Shi X, Tang H, Zhang T, Wang Y, Shen C, et al. Thyroid-stimulating hormone suppression in low-risk papillary thyroid cancer: a large-scale retrospective analysis of real-world data. EClinicalMedicine. 2024 Oct 30;77:102912.
8.Hou Y, Lin B, Xu T, Jiang J, Luo S, Chen W, et al. The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer. Nat Commun. 2024; 15: 5555.
9.Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Uncovering the connection between obesity and thyroid cancer: the therapeutic potential of adiponectin receptor agonist in the AdipoR2-ULK axis. Cell Death Dis. 2024; 15: 708.
10.Zhang W, Ruan X, Huang Y, Zhang W, Xu G, Zhao J, et al. SETMAR Facilitates the Differentiation of Thyroid Cancer by Regulating SMARCA2-Mediated Chromatin Remodeling. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024; 11: e2401712.
11.Shi X, Tang H, Zhang T, Wang Y, Shen C, Zhang Y, et al. Thyroid-stimulating hormone suppression in low-risk papillary thyroid cancer: a large-scale retrospective analysis of real-world data. EClinicalMedicine. 2024; 77: 102912.
12.Yan K, Liu QZ, Huang RR, Jiang YH, Bian ZH, Li SJ, et al. Spatial transcriptomics reveals prognosis-associated cellular heterogeneity in the papillary thyroid carcinoma microenvironment. Clin Transl Med. 2024; 14: e1594.
13.郭丝锦,延常姣,王洋,等. 分化型甲状腺癌人工智能语音随访系统的构建及应用 [J]. 实用临床医药杂志, 2024, 28 (16): 1-4+9.
14.计成,饶惠珍,朱巧玲,等. 人工智能系统在分化型甲状腺癌术后患者中的应用与评价 [J]. 药学与临床研究, 2022, 30 (3): 271-275.
15.Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, et al. Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA oncology. 2024; 10: 1663-71.
16.Yi Seah X, Tham XC, Aloweni F, Kua SMY, Tham WY, Lim SH. Reducing anxiety and enhancing satisfaction in thyroid patients with DietLens application during radioactive iodine therapy: A quasi-experimental study. Heliyon. 2024; 10: e35450.
17.Kim M, Hwang SY. Development and Effects of a Smartphone Application to Improve Self-Management in Workers Who Underwent Thyroid Cancer Surgery. Cancer Nurs. 2025.
18.Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, et al. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan. Thyroid : official journal of the American Thyroid Association. 2024; 34: 467-76.
19.Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, et al. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA oncology. 2024; 10: 1672-80.
20.Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjörnsdottir S, Jonasson C, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. Bmj. 2024; 385: e078225.
21.Han PZ, Ye WD, Yu PC, Tan LC, Shi X, Chen XF, et al. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI insight. 2024; 9.
22.Wang F, Lin Y, Qin L, Zeng X, Jiang H, Liang Y, et al. Serum metabolome associated with novel and legacy per- and polyfluoroalkyl substances exposure and thyroid cancer risk: A multi-module integrated analysis based on machine learning. Environ Int. 2025; 195: 109203.
23.Tang Y, Wang R, Xu Z, Wang J, Zhou D, Zhang S, et al. Contribution of Cancer-Specific Protein Coronas to the Pro-Tumor Effects of Nanoplastics through Enhanced Cellular Interactions. ACS Appl Mater Interfaces. 2024; 16: 65540-52.
24.Zheng G, Chen S, Ma W, Wang Q, Sun L, Zhang C, et al. Spatial and Single-Cell Transcriptomics Unraveled Spatial Evolution of Papillary Thyroid Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025; 12: e2404491.
25.中国抗癌协会肿瘤消融治疗专业委员会,中国临床肿瘤学会(CSCO)肿瘤消融专家委员会,中国医师协会介入医师分会肿瘤消融专业委员会,等. 甲状腺乳头状癌热消融治疗专家共识(2024版)[J]. 中华内科杂志,2024,63(04):355-364.]
26.Qu N, Chen D, Ma B, Zhang L, Wang Q, Wang Y, et al. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks. Nat Commun. 2024; 15: 3175.
27.Li W, Wang Y, Xiong A, Gao G, Song Z, Zhang Y, et al. First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors. Signal Transduct Target Ther. 2024; 9: 300.